Unknown

Dataset Information

0

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.


ABSTRACT: PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance is common. Multiple resistance mechanisms have been described, including secondary mutations that restore the HR gene reading frame. BRCA1 splice isoforms △11 and △11q can contribute to PARPi resistance by splicing out the mutation-containing exon, producing truncated, partially functional proteins. However, the clinical impacts and underlying drivers of BRCA1 exon skipping are not fully understood.We analyzed nine ovarian and breast cancer patient derived xenografts (PDX) with BRCA1 exon 11 frameshift mutations for exon skipping and therapy response, including a matched PDX pair derived from a patient pre- and post-chemotherapy/PARPi. BRCA1 exon 11 skipping was elevated in PARPi resistant PDX tumors. Two independent PDX models acquired secondary BRCA1 splice site mutations (SSMs) that drive exon skipping, confirmed using qRT-PCR, RNA sequencing, immunoblotting and minigene modelling. CRISPR/Cas9-mediated disruption of splicing functionally validated exon skipping as a mechanism of PARPi resistance. SSMs were also enriched in post-PARPi ovarian cancer patient cohorts from the ARIEL2 and ARIEL4 clinical trials.Few PARPi resistance mechanisms have been confirmed in the clinical setting. While secondary/reversion mutations typically restore a gene's reading frame, we have identified secondary mutations in patient cohorts that hijack splice sites to enhance mutation-containing exon skipping, resulting in the overexpression of BRCA1 hypomorphs, which in turn promote PARPi resistance. Thus, BRCA1 SSMs can and should be clinically monitored, along with frame-restoring secondary mutations.

SUBMITTER: Nesic K 

PROVIDER: S-EPMC11299415 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Nesic Ksenija K   Krais John J JJ   Wang Yifan Y   Vandenberg Cassandra J CJ   Patel Pooja P   Cai Kathy Q KQ   Kwan Tanya T   Lieschke Elizabeth E   Ho Gwo-Yaw GY   Barker Holly E HE   Bedo Justin J   Casadei Silvia S   Farrell Andrew A   Radke Marc M   Shield-Artin Kristy K   Penington Jocelyn S JS   Geissler Franziska F   Kyran Elizabeth E   Betsch Robert R   Xu Lijun L   Zhang Fan F   Dobrovic Alexander A   Olesen Inger I   Kristeleit Rebecca R   Oza Amit A   McNeish Iain I   Ratnayake Gayanie G   Traficante Nadia N   DeFazio Anna A   Bowtell David D L DDL   Harding Thomas C TC   Lin Kevin K   Swisher Elizabeth M EM   Kondrashova Olga O   Scott Clare L CL   Johnson Neil N   Wakefield Matthew J MJ  

Molecular cancer 20240805 1


PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance is common. Multiple resistance mechanisms have been described, including secondary mutations that restore the HR gene reading frame. BRCA1 splice isoforms △11 and △11q can contribute to PARPi resistance by splicing out the mutation-containing exon, producing truncated, par  ...[more]

Similar Datasets

| S-EPMC10055590 | biostudies-literature
| S-EPMC8946549 | biostudies-literature
| S-EPMC2947103 | biostudies-literature
| S-EPMC6906494 | biostudies-literature
| S-EPMC10473960 | biostudies-literature
| S-EPMC1712487 | biostudies-other
| S-EPMC3324353 | biostudies-literature
| S-EPMC9639565 | biostudies-literature
2023-07-18 | PXD040430 | Pride
| S-EPMC9225289 | biostudies-literature